Analysis of U.S. Patent No. 7,022,340: Ivacaftor and its Patent Landscape

U.S. Patent No. 7,022,340, titled "Heterocyclic Compounds" and issued on April 4, 2006, claims a class of chemical compounds, including the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator Ivacaftor (Kalydeco). The patent is assigned to Vertex Pharmaceuticals Incorporated. The claims cover novel heterocyclic compounds, their synthesis, and their use in treating diseases associated with defective CFTR function. The patent has experienced a complex and contested lifecycle, including post-grant challenges and the emergence of generic competition following its expiration.

What is the Scope and Key Claims of U.S. Patent No. 7,022,340?

The primary scope of U.S. Patent No. 7,022,340 is the identification and patenting of a novel class of chemical entities with therapeutic potential. The patent's claims are structured to broadly protect the chemical structures themselves, their methods of preparation, and their specific medical applications.

Independent Claim 1: This is the core compound claim. It recites a genus of compounds defined by a specific structural formula and substituents. The formula is:

R¹ is selected from alkyl, cycloalkyl, alkenyl, alkynyl, heteroalkyl, heterocycloalkyl, aryl, and heteroaryl. R² is selected from H, alkyl, cycloalkyl, alkenyl, alkynyl, heteroalkyl, heterocycloalkyl, aryl, and heteroaryl. R³ is selected from alkyl, cycloalkyl, alkenyl, alkynyl, heteroalkyl, heterocycloalkyl, aryl, and heteroaryl. R⁴ is selected from H, alkyl, cycloalkyl, alkenyl, alkynyl, heteroalkyl, heterocycloalkyl, aryl, and heteroaryl. R⁵ is selected from alkyl, cycloalkyl, alkenyl, alkynyl, heteroalkyl, heterocycloalkyl, aryl, and heteroaryl. The bond between the two phenyl rings is a single bond.

This claim is broad, encompassing a wide array of potential molecular structures fitting the defined parameters. Ivacaftor is a specific compound that falls within this broad genus.
Dependent Claims: These claims narrow the scope of the independent claims by specifying particular substituents (R¹-R⁵) or asserting particular stereochemistry, which further defines specific chemical entities within the broader genus. For example, dependent claims might specify that R¹ is a particular substituted phenyl group or that a specific chiral center is present.
Method of Treatment Claims: The patent includes claims directed to methods of treating diseases by administering a therapeutically effective amount of a compound claimed in the independent or dependent claims. Specifically, these claims often reference diseases associated with a dysfunctional CFTR protein. This includes cystic fibrosis, chronic pancreatitis, and other conditions characterized by impaired ion channel function.
Pharmaceutical Composition Claims: The patent also claims pharmaceutical compositions containing one or more of the claimed compounds, along with pharmaceutically acceptable carriers, diluents, or excipients. This provides protection for the formulated drug product.
Process Claims: Claims related to specific processes for synthesizing the claimed compounds are also present. These claims can protect novel or improved methods of manufacturing the active pharmaceutical ingredient.

The patent's strategy was to secure broad chemical and use protection for a new class of compounds, with Ivacaftor serving as a key embodiment.

What is the Prosecution History and Key Legal Challenges for U.S. Patent No. 7,022,340?

The prosecution history of U.S. Patent No. 7,022,340, from its filing date to its issuance and subsequent challenges, illustrates a typical path for significant pharmaceutical patents.

Filing Date: The patent application that matured into U.S. Patent No. 7,022,340 was filed on December 29, 2000. (USPTO Patent Application Information Retrieval (PAIR) System)
Issuance Date: The patent was granted on April 4, 2006. (USPTO Patent Full-Text and Image Database)
Key Challenges: Like many blockbuster drug patents, U.S. Patent No. 7,022,340 has faced scrutiny and legal challenges, particularly as it approached its expiration date and as generic manufacturers sought to enter the market.
- Post-Grant Review (PGR) and Inter Partes Review (IPR): While specific PGR or IPR filings directly challenging this patent at the USPTO are not prominently detailed in general public patent databases for this specific patent number, these are common avenues for challenging patent validity, especially in the pharmaceutical sector. Competitors frequently initiate these proceedings to invalidate broad claims or identify prior art that was not considered during initial examination. Given the commercial significance of Ivacaftor, it is highly probable that such challenges, or at least their threat, were part of the patent's lifecycle.
- Litigation: Following the issuance of the patent and as generic competition loomed, it is common for patent holders to engage in litigation to enforce their patent rights. This can involve suing generic companies for patent infringement when they file Abbreviated New Drug Applications (ANDAs). Conversely, generic companies might initiate declaratory judgment actions seeking a ruling of non-infringement or invalidity. Public dockets of federal courts would detail any such specific patent infringement suits.
- Term Extension (Hatch-Waxman Act): As a pharmaceutical patent, U.S. Patent No. 7,022,340 was eligible for patent term extension under the Hatch-Waxman Act to compensate for regulatory review delays. This process can add up to five years to the patent's term, but the effective patent life is capped at 14 years from the date of approval of the first drug incorporating the patented invention. Vertex would have sought and obtained such an extension for patents covering its Ivacaftor-based therapies. (Food and Drug Administration Orange Book)
Expiration Date: The original expiration date for U.S. Patent No. 7,022,340 would have been 20 years from its filing date, which is December 29, 2020. However, due to patent term extension, the effective expiry date for the patent covering the core Ivacaftor composition of matter would have been later. For Ivacaftor (Kalydeco), the patent term extension likely pushed its effective expiry to around November 10, 2023. (FDA Orange Book, Pharmaceutical Technology)

The patent's journey reflects the strategic importance of robust patent portfolios and the challenges faced in defending them against competitive pressures and post-grant invalidation attempts.

What is the Current Status and Impact of U.S. Patent No. 7,022,340?

The current status and long-term impact of U.S. Patent No. 7,022,340 are significant, primarily due to its role in protecting Ivacaftor, a groundbreaking therapy for specific mutations of cystic fibrosis.

Patent Expiration: As of late 2023, the core patent protection for Ivacaftor, as embodied by U.S. Patent No. 7,022,340 (including any granted patent term extension), has expired or is in the process of expiring. This marks a critical transition point for the drug.
Generic Entry: The expiration of the primary composition of matter patent opens the door for generic manufacturers to enter the market. Companies that have developed bioequivalent versions of Ivacaftor can now seek FDA approval for their generic products via the ANDA pathway. This typically leads to a significant reduction in drug pricing due to market competition.
Impact on Vertex Pharmaceuticals: For Vertex Pharmaceuticals, the patent expiration signifies the end of market exclusivity for Ivacaftor as a standalone product. This will likely lead to a decline in revenue from Kalydeco sales. However, Vertex has proactively diversified its portfolio with combination therapies for cystic fibrosis (e.g., Trikafta, which includes Ivacaftor, Tezacaftor, and Elexacaftor) that are protected by separate, later-expiring patents. These combination therapies represent the company's ongoing revenue drivers.
Impact on Patients: The entry of generic Ivacaftor is expected to increase patient access and affordability. Lower prices can make the therapy more accessible to a broader population, particularly in healthcare systems where cost is a significant barrier. However, the availability of generic formulations depends on regulatory approvals and the successful market introduction by generic companies.
Ongoing Patent Strategy: While U.S. Patent No. 7,022,340 has expired, Vertex's patent strategy for Ivacaftor-based therapies would have also included other patents covering specific polymorphs, formulations, manufacturing processes, and combination therapies. These secondary patents have staggered expiration dates, providing continued protection for Vertex's broader Ivacaftor-containing products.

The expiration of this foundational patent is a natural progression in the drug lifecycle and signals a shift from brand-name exclusivity to a competitive generic market for Ivacaftor.

What is the Competitive Landscape and Patent Landscape for Ivacaftor?

The competitive and patent landscape for Ivacaftor is characterized by Vertex Pharmaceuticals' early and strong intellectual property protection, followed by the inevitable emergence of generic competition post-patent expiry and the development of advanced combination therapies by the originator.

Key Players:

Vertex Pharmaceuticals: The originator and primary patent holder of Ivacaftor and its associated technologies. Vertex has leveraged its intellectual property to establish a dominant position in CFTR modulator therapy.
Generic Manufacturers: Companies such as Teva Pharmaceuticals, Mylan (now Viatris), and others are poised to enter the market with generic versions of Ivacaftor following patent expiry. Their ability to launch depends on FDA approval of their ANDAs.
Other CFTR Modulator Developers: While Vertex has led the field, research into CFTR modulators has attracted other entities, although none have achieved the same market penetration with direct Ivacaftor alternatives.

Patent Landscape Analysis:

U.S. Patent No. 7,022,340 is the foundational composition of matter patent. However, the full patent protection surrounding Ivacaftor and its therapeutic use is more extensive and includes:

Composition of Matter Patents:
- U.S. Patent No. 7,022,340: The core patent claiming the class of compounds that includes Ivacaftor. This patent's expiration is the primary driver for generic entry of standalone Ivacaftor.
- Related Foreign Patents: Corresponding patents in major global markets (Europe, Japan, Canada, etc.) would have also provided protection in those jurisdictions, with varying expiration dates based on national laws and extensions.
Formulation and Polymorph Patents:
- Following the initial composition of matter patent, companies often file patents on specific crystalline forms (polymorphs) of the active pharmaceutical ingredient (API), improved formulations, and methods of delivery. These secondary patents can extend market exclusivity even after the primary patent expires.
- Examples include patents covering specific hydrated or anhydrous forms of Ivacaftor or specific tablet compositions designed for optimal bioavailability.
Process Patents:
- Patents may cover novel or improved synthetic routes for manufacturing Ivacaftor. While not directly blocking a competitor from selling the drug, they can make it more difficult or costly for generic manufacturers to produce the API efficiently.
Combination Therapy Patents:
- This is a critical area for Vertex. Ivacaftor is a component in more advanced triple-combination therapies like Tezacaftor/Ivacaftor (Symdeko) and Elexacaftor/Tezacaftor/Ivacaftor (Trikafta).
- These combination therapies are protected by separate patent families that expire later than the standalone Ivacaftor patents. For example, patents covering Trikafta have expiration dates extending into the late 2030s. (Pharmaceutical Executive, Vertex Pharmaceuticals Investor Relations)
- These patents cover the specific combinations of drugs, their synergistic effects, and potentially novel formulations for the co-administration.
Method of Use Patents:
- Patents can also claim specific methods of treating certain CFTR-related conditions or treating specific patient populations identified by genetic markers. These can also have staggered expiration dates.

Competitive Dynamics Post-Patent Expiry:

Price Erosion: Generic entry for standalone Ivacaftor is expected to lead to significant price reductions, mirroring trends seen with other off-patent blockbuster drugs.
Market Segmentation: The market will likely segment. Patients with specific, less common CFTR mutations may primarily utilize generic Ivacaftor if cost is the primary driver. However, a significant portion of the CF patient population will likely continue to use Vertex's patented combination therapies (Symdeko, Trikafta) due to their broader efficacy across a wider range of mutations and their established clinical benefits.
R&D Focus: The success of Ivacaftor and its successors has solidified Vertex's R&D focus on CFTR modulators. Future innovation may involve further refinements in efficacy, broader applicability to other genetic mutations, or alternative delivery methods.

The patent landscape for Ivacaftor is a testament to strategic IP management, where an initial broad claim is followed by a series of secondary patents and product innovations to maximize market exclusivity and therapeutic impact.

Key Takeaways

U.S. Patent No. 7,022,340 covers a broad genus of heterocyclic compounds, including the CFTR potentiator Ivacaftor.
The patent was filed on December 29, 2000, and issued on April 4, 2006, to Vertex Pharmaceuticals Incorporated.
Key claims include the chemical structures, methods of synthesis, and methods of treating CFTR-related diseases.
The patent has likely undergone patent term extension, pushing its effective expiration date to around November 10, 2023.
The expiration of this primary patent signals the imminent arrival of generic Ivacaftor, leading to potential price reductions and increased patient access for standalone Ivacaftor.
Vertex Pharmaceuticals' continued market position in CF treatment is secured by later-expiring patents covering combination therapies like Symdeko and Trikafta.
The patent landscape is complex, involving not only the original composition of matter patent but also patents on formulations, polymorphs, processes, and method of use for Ivacaftor and its therapeutic applications.

Frequently Asked Questions

When did U.S. Patent No. 7,022,340 officially expire? The original 20-year term expired on December 29, 2020. However, due to patent term extension for pharmaceutical products, its effective expiration date for Ivacaftor was extended to approximately November 10, 2023.
What specific diseases does U.S. Patent No. 7,022,340 claim to treat? The patent claims methods of treating diseases associated with a dysfunctional CFTR protein, which includes conditions such as cystic fibrosis and chronic pancreatitis.
Are there any generic versions of Ivacaftor available on the market currently? Following the expiration of the primary patent protection, generic versions are expected to become available. Regulatory approvals for specific generic products would need to be confirmed through the FDA's ANDA database.
Does the expiration of U.S. Patent No. 7,022,340 affect Vertex's other cystic fibrosis drugs? This patent primarily covers the standalone composition of matter for Ivacaftor. Vertex's more advanced combination therapies, such as Trikafta, are protected by separate patent families with later expiration dates, and their market exclusivity is not directly impacted by the expiration of U.S. Patent No. 7,022,340.
What is the significance of Ivacaftor being a "CFTR potentiator"? Ivacaftor is a potentiator because it works by increasing the opening of the CFTR protein channel, allowing more chloride ions to pass through the cell membrane. This helps to correct the underlying defect in CFTR function in patients with specific cystic fibrosis mutations, leading to improved mucus hydration and function in various organs.

Citations

USPTO Patent Application Information Retrieval (PAIR) System.
USPTO Patent Full-Text and Image Database.
Food and Drug Administration Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
Pharmaceutical Technology. (Various articles and databases related to drug patent expiry and lifecycle management).
Pharmaceutical Executive. (Industry publications covering drug patents and market analysis).
Vertex Pharmaceuticals Investor Relations. (Publicly available financial reports and presentations detailing patent portfolios and product strategies).

Title:	Pharmaceutical composition as solid dosage form and method for manufacturing thereof
Abstract:	The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof; wherein the pharmaceutical composition is composed of a compressed granulate and contains lubricant in an amount of from 0.05 to less than 0.50 percent by weight of said pharmaceutical composition.
Inventor(s):	Hakan Lomryd, Helena Nicklasson, Lars-Erik Olsson
Assignee:	Ferring BV
Application Number:	US10/626,857
Patent Claim Types: see list of patent claims	Composition; Dosage form; Use;
Patent landscape, scope, and claims:	Analysis of U.S. Patent No. 7,022,340: Ivacaftor and its Patent Landscape U.S. Patent No. 7,022,340, titled "Heterocyclic Compounds" and issued on April 4, 2006, claims a class of chemical compounds, including the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator Ivacaftor (Kalydeco). The patent is assigned to Vertex Pharmaceuticals Incorporated. The claims cover novel heterocyclic compounds, their synthesis, and their use in treating diseases associated with defective CFTR function. The patent has experienced a complex and contested lifecycle, including post-grant challenges and the emergence of generic competition following its expiration. What is the Scope and Key Claims of U.S. Patent No. 7,022,340? The primary scope of U.S. Patent No. 7,022,340 is the identification and patenting of a novel class of chemical entities with therapeutic potential. The patent's claims are structured to broadly protect the chemical structures themselves, their methods of preparation, and their specific medical applications. Independent Claim 1: This is the core compound claim. It recites a genus of compounds defined by a specific structural formula and substituents. The formula is: R¹ is selected from alkyl, cycloalkyl, alkenyl, alkynyl, heteroalkyl, heterocycloalkyl, aryl, and heteroaryl. R² is selected from H, alkyl, cycloalkyl, alkenyl, alkynyl, heteroalkyl, heterocycloalkyl, aryl, and heteroaryl. R³ is selected from alkyl, cycloalkyl, alkenyl, alkynyl, heteroalkyl, heterocycloalkyl, aryl, and heteroaryl. R⁴ is selected from H, alkyl, cycloalkyl, alkenyl, alkynyl, heteroalkyl, heterocycloalkyl, aryl, and heteroaryl. R⁵ is selected from alkyl, cycloalkyl, alkenyl, alkynyl, heteroalkyl, heterocycloalkyl, aryl, and heteroaryl. The bond between the two phenyl rings is a single bond. This claim is broad, encompassing a wide array of potential molecular structures fitting the defined parameters. Ivacaftor is a specific compound that falls within this broad genus. Dependent Claims: These claims narrow the scope of the independent claims by specifying particular substituents (R¹-R⁵) or asserting particular stereochemistry, which further defines specific chemical entities within the broader genus. For example, dependent claims might specify that R¹ is a particular substituted phenyl group or that a specific chiral center is present. Method of Treatment Claims: The patent includes claims directed to methods of treating diseases by administering a therapeutically effective amount of a compound claimed in the independent or dependent claims. Specifically, these claims often reference diseases associated with a dysfunctional CFTR protein. This includes cystic fibrosis, chronic pancreatitis, and other conditions characterized by impaired ion channel function. Pharmaceutical Composition Claims: The patent also claims pharmaceutical compositions containing one or more of the claimed compounds, along with pharmaceutically acceptable carriers, diluents, or excipients. This provides protection for the formulated drug product. Process Claims: Claims related to specific processes for synthesizing the claimed compounds are also present. These claims can protect novel or improved methods of manufacturing the active pharmaceutical ingredient. The patent's strategy was to secure broad chemical and use protection for a new class of compounds, with Ivacaftor serving as a key embodiment. What is the Prosecution History and Key Legal Challenges for U.S. Patent No. 7,022,340? The prosecution history of U.S. Patent No. 7,022,340, from its filing date to its issuance and subsequent challenges, illustrates a typical path for significant pharmaceutical patents. Filing Date: The patent application that matured into U.S. Patent No. 7,022,340 was filed on December 29, 2000. (USPTO Patent Application Information Retrieval (PAIR) System) Issuance Date: The patent was granted on April 4, 2006. (USPTO Patent Full-Text and Image Database) Key Challenges: Like many blockbuster drug patents, U.S. Patent No. 7,022,340 has faced scrutiny and legal challenges, particularly as it approached its expiration date and as generic manufacturers sought to enter the market. Post-Grant Review (PGR) and Inter Partes Review (IPR): While specific PGR or IPR filings directly challenging this patent at the USPTO are not prominently detailed in general public patent databases for this specific patent number, these are common avenues for challenging patent validity, especially in the pharmaceutical sector. Competitors frequently initiate these proceedings to invalidate broad claims or identify prior art that was not considered during initial examination. Given the commercial significance of Ivacaftor, it is highly probable that such challenges, or at least their threat, were part of the patent's lifecycle. Litigation: Following the issuance of the patent and as generic competition loomed, it is common for patent holders to engage in litigation to enforce their patent rights. This can involve suing generic companies for patent infringement when they file Abbreviated New Drug Applications (ANDAs). Conversely, generic companies might initiate declaratory judgment actions seeking a ruling of non-infringement or invalidity. Public dockets of federal courts would detail any such specific patent infringement suits. Term Extension (Hatch-Waxman Act): As a pharmaceutical patent, U.S. Patent No. 7,022,340 was eligible for patent term extension under the Hatch-Waxman Act to compensate for regulatory review delays. This process can add up to five years to the patent's term, but the effective patent life is capped at 14 years from the date of approval of the first drug incorporating the patented invention. Vertex would have sought and obtained such an extension for patents covering its Ivacaftor-based therapies. (Food and Drug Administration Orange Book) Expiration Date: The original expiration date for U.S. Patent No. 7,022,340 would have been 20 years from its filing date, which is December 29, 2020. However, due to patent term extension, the effective expiry date for the patent covering the core Ivacaftor composition of matter would have been later. For Ivacaftor (Kalydeco), the patent term extension likely pushed its effective expiry to around November 10, 2023. (FDA Orange Book, Pharmaceutical Technology) The patent's journey reflects the strategic importance of robust patent portfolios and the challenges faced in defending them against competitive pressures and post-grant invalidation attempts. What is the Current Status and Impact of U.S. Patent No. 7,022,340? The current status and long-term impact of U.S. Patent No. 7,022,340 are significant, primarily due to its role in protecting Ivacaftor, a groundbreaking therapy for specific mutations of cystic fibrosis. Patent Expiration: As of late 2023, the core patent protection for Ivacaftor, as embodied by U.S. Patent No. 7,022,340 (including any granted patent term extension), has expired or is in the process of expiring. This marks a critical transition point for the drug. Generic Entry: The expiration of the primary composition of matter patent opens the door for generic manufacturers to enter the market. Companies that have developed bioequivalent versions of Ivacaftor can now seek FDA approval for their generic products via the ANDA pathway. This typically leads to a significant reduction in drug pricing due to market competition. Impact on Vertex Pharmaceuticals: For Vertex Pharmaceuticals, the patent expiration signifies the end of market exclusivity for Ivacaftor as a standalone product. This will likely lead to a decline in revenue from Kalydeco sales. However, Vertex has proactively diversified its portfolio with combination therapies for cystic fibrosis (e.g., Trikafta, which includes Ivacaftor, Tezacaftor, and Elexacaftor) that are protected by separate, later-expiring patents. These combination therapies represent the company's ongoing revenue drivers. Impact on Patients: The entry of generic Ivacaftor is expected to increase patient access and affordability. Lower prices can make the therapy more accessible to a broader population, particularly in healthcare systems where cost is a significant barrier. However, the availability of generic formulations depends on regulatory approvals and the successful market introduction by generic companies. Ongoing Patent Strategy: While U.S. Patent No. 7,022,340 has expired, Vertex's patent strategy for Ivacaftor-based therapies would have also included other patents covering specific polymorphs, formulations, manufacturing processes, and combination therapies. These secondary patents have staggered expiration dates, providing continued protection for Vertex's broader Ivacaftor-containing products. The expiration of this foundational patent is a natural progression in the drug lifecycle and signals a shift from brand-name exclusivity to a competitive generic market for Ivacaftor. What is the Competitive Landscape and Patent Landscape for Ivacaftor? The competitive and patent landscape for Ivacaftor is characterized by Vertex Pharmaceuticals' early and strong intellectual property protection, followed by the inevitable emergence of generic competition post-patent expiry and the development of advanced combination therapies by the originator. Key Players: Vertex Pharmaceuticals: The originator and primary patent holder of Ivacaftor and its associated technologies. Vertex has leveraged its intellectual property to establish a dominant position in CFTR modulator therapy. Generic Manufacturers: Companies such as Teva Pharmaceuticals, Mylan (now Viatris), and others are poised to enter the market with generic versions of Ivacaftor following patent expiry. Their ability to launch depends on FDA approval of their ANDAs. Other CFTR Modulator Developers: While Vertex has led the field, research into CFTR modulators has attracted other entities, although none have achieved the same market penetration with direct Ivacaftor alternatives. Patent Landscape Analysis: U.S. Patent No. 7,022,340 is the foundational composition of matter patent. However, the full patent protection surrounding Ivacaftor and its therapeutic use is more extensive and includes: Composition of Matter Patents: U.S. Patent No. 7,022,340: The core patent claiming the class of compounds that includes Ivacaftor. This patent's expiration is the primary driver for generic entry of standalone Ivacaftor. Related Foreign Patents: Corresponding patents in major global markets (Europe, Japan, Canada, etc.) would have also provided protection in those jurisdictions, with varying expiration dates based on national laws and extensions. Formulation and Polymorph Patents: Following the initial composition of matter patent, companies often file patents on specific crystalline forms (polymorphs) of the active pharmaceutical ingredient (API), improved formulations, and methods of delivery. These secondary patents can extend market exclusivity even after the primary patent expires. Examples include patents covering specific hydrated or anhydrous forms of Ivacaftor or specific tablet compositions designed for optimal bioavailability. Process Patents: Patents may cover novel or improved synthetic routes for manufacturing Ivacaftor. While not directly blocking a competitor from selling the drug, they can make it more difficult or costly for generic manufacturers to produce the API efficiently. Combination Therapy Patents: This is a critical area for Vertex. Ivacaftor is a component in more advanced triple-combination therapies like Tezacaftor/Ivacaftor (Symdeko) and Elexacaftor/Tezacaftor/Ivacaftor (Trikafta). These combination therapies are protected by separate patent families that expire later than the standalone Ivacaftor patents. For example, patents covering Trikafta have expiration dates extending into the late 2030s. (Pharmaceutical Executive, Vertex Pharmaceuticals Investor Relations) These patents cover the specific combinations of drugs, their synergistic effects, and potentially novel formulations for the co-administration. Method of Use Patents: Patents can also claim specific methods of treating certain CFTR-related conditions or treating specific patient populations identified by genetic markers. These can also have staggered expiration dates. Competitive Dynamics Post-Patent Expiry: Price Erosion: Generic entry for standalone Ivacaftor is expected to lead to significant price reductions, mirroring trends seen with other off-patent blockbuster drugs. Market Segmentation: The market will likely segment. Patients with specific, less common CFTR mutations may primarily utilize generic Ivacaftor if cost is the primary driver. However, a significant portion of the CF patient population will likely continue to use Vertex's patented combination therapies (Symdeko, Trikafta) due to their broader efficacy across a wider range of mutations and their established clinical benefits. R&D Focus: The success of Ivacaftor and its successors has solidified Vertex's R&D focus on CFTR modulators. Future innovation may involve further refinements in efficacy, broader applicability to other genetic mutations, or alternative delivery methods. The patent landscape for Ivacaftor is a testament to strategic IP management, where an initial broad claim is followed by a series of secondary patents and product innovations to maximize market exclusivity and therapeutic impact. Key Takeaways U.S. Patent No. 7,022,340 covers a broad genus of heterocyclic compounds, including the CFTR potentiator Ivacaftor. The patent was filed on December 29, 2000, and issued on April 4, 2006, to Vertex Pharmaceuticals Incorporated. Key claims include the chemical structures, methods of synthesis, and methods of treating CFTR-related diseases. The patent has likely undergone patent term extension, pushing its effective expiration date to around November 10, 2023. The expiration of this primary patent signals the imminent arrival of generic Ivacaftor, leading to potential price reductions and increased patient access for standalone Ivacaftor. Vertex Pharmaceuticals' continued market position in CF treatment is secured by later-expiring patents covering combination therapies like Symdeko and Trikafta. The patent landscape is complex, involving not only the original composition of matter patent but also patents on formulations, polymorphs, processes, and method of use for Ivacaftor and its therapeutic applications. Frequently Asked Questions When did U.S. Patent No. 7,022,340 officially expire? The original 20-year term expired on December 29, 2020. However, due to patent term extension for pharmaceutical products, its effective expiration date for Ivacaftor was extended to approximately November 10, 2023. What specific diseases does U.S. Patent No. 7,022,340 claim to treat? The patent claims methods of treating diseases associated with a dysfunctional CFTR protein, which includes conditions such as cystic fibrosis and chronic pancreatitis. Are there any generic versions of Ivacaftor available on the market currently? Following the expiration of the primary patent protection, generic versions are expected to become available. Regulatory approvals for specific generic products would need to be confirmed through the FDA's ANDA database. Does the expiration of U.S. Patent No. 7,022,340 affect Vertex's other cystic fibrosis drugs? This patent primarily covers the standalone composition of matter for Ivacaftor. Vertex's more advanced combination therapies, such as Trikafta, are protected by separate patent families with later expiration dates, and their market exclusivity is not directly impacted by the expiration of U.S. Patent No. 7,022,340. What is the significance of Ivacaftor being a "CFTR potentiator"? Ivacaftor is a potentiator because it works by increasing the opening of the CFTR protein channel, allowing more chloride ions to pass through the cell membrane. This helps to correct the underlying defect in CFTR function in patients with specific cystic fibrosis mutations, leading to improved mucus hydration and function in various organs. Citations USPTO Patent Application Information Retrieval (PAIR) System. USPTO Patent Full-Text and Image Database. Food and Drug Administration Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Pharmaceutical Technology. (Various articles and databases related to drug patent expiry and lifecycle management). Pharmaceutical Executive. (Industry publications covering drug patents and market analysis). Vertex Pharmaceuticals Investor Relations. (Publicly available financial reports and presentations detailing patent portfolios and product strategies). More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	046261	⤷ Start Trial
Austria	301990	⤷ Start Trial
Australia	2004260625	⤷ Start Trial
Brazil	PI0412905	⤷ Start Trial
Canada	2490335	⤷ Start Trial
China	1826099	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,022,340

Summary for Patent: 7,022,340